Clinically palpable breast abnormalities with normal imaging: Is clinically guided biopsy still required?

Basit Öğe Kaydı
dc.contributor.authorGumus, H.
dc.contributor.authorGumus, M.
dc.contributor.authorMills, P.
dc.contributor.authorFish, D.
dc.contributor.authorDevalia, H.
dc.contributor.authorJones, S. E.
dc.contributor.authorJones, P. A.
dc.date.accessioned2024-04-24T16:11:12Z
dc.date.available2024-04-24T16:11:12Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractAIM: To determine the need for a fine-needle or core biopsy in patients with clinically palpable breast abnormalities who have negative mammographic and sonographic findings. METHOD AND MATERIALS: Over a 12-year period, 251 patients with a palpable abnormality at presentation and who had a negative ultrasound and mammogram underwent clinically guided biopsy (CGB) by breast surgeons. This was 2.7% (251/9313) of all breast biopsies performed from January 1999 to December 2010. Physical findings were qualitatively categorized into five groups as clinically normal, benign, probably benign, suspicious, and malignant at the time of initial assessment. The number of biopsies for each category and biopsy results were analysed retrospectively. RESULTS: Three (1.2%) of the 251 CGBs were reported as malignant; two (0.8%) of which were invasive. Forty-six (18.3%) of the 251 cases were regarded as clinically suspicious or malignant while the remaining 215 examinations were categorized as benign or probably benign. All three malignancies were in the clinically suspicious or malignant group. CONCLUSION: A negative ultrasound and mammogram in patients with a palpable abnormality does not exclude breast cancer; however, the likelihood is very low (1.2%). In this study, 81.7% of biopsies (205/251) could have been avoided if CGB was reserved for the clinically suspicious or malignant group only without missing any malignancies. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.crad.2011.10.010
dc.identifier.endpage440en_US
dc.identifier.issn0009-9260
dc.identifier.issn1365-229X
dc.identifier.issue5en_US
dc.identifier.pmid22119297
dc.identifier.scopus2-s2.0-84859426648
dc.identifier.scopusqualityQ2
dc.identifier.startpage437en_US
dc.identifier.urihttps://doi.org/10.1016/j.crad.2011.10.010
dc.identifier.urihttps://hdl.handle.net/11468/15310
dc.identifier.volume67en_US
dc.identifier.wosWOS:000303098600006
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherW B Saunders Co Ltden_US
dc.relation.ispartofClinical Radiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keyword]en_US
dc.titleClinically palpable breast abnormalities with normal imaging: Is clinically guided biopsy still required?en_US
dc.titleClinically palpable breast abnormalities with normal imaging: Is clinically guided biopsy still required?
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu